FDA Wants Additional Data on Centocor Psoriasis Drug

The Food and Drug Administration wants additional information on Ustekinumab before approving it...

» read full story

December 22nd, 2008 - 15:45

FDA Requests More Information On Psoriasis Drug

Centocor Inc., a unit of Johnson & Johnson, announced yesterday that federal health regulators...

» read full story

December 20th, 2008 - 19:16

Johnson & Johnson’s Ustekinumab Drug Declined By FDA

The FDA declined the approval of Johnson & Johnson’s ne anti-inflammatory drug,...

» read full story

December 20th, 2008 - 17:28

New Revolutionary Drug For Treatment of Psoriasis

Johnson & Johnson introduced an experimental drug called ustekinumab that is said to show...

» read full story

September 21st, 2008 - 17:43

New Experimental Drug Much Better For Psoriasis

A recent short term trial reached the conclusion that an experimental drug called Ustekinumab,...

» read full story

September 21st, 2008 - 14:43

J&J Psoriasis Drug Meets Goal In Trial, Defeats Rival Enbrel

Johnson & Johnson unveiled Thursday results of a late-stage trial that showed its psoriasis...

» read full story

September 19th, 2008 - 14:11

FDA Says J&J Psoriasis Drug Could Increase Cancer Risk

The FDA reviwers noted in a analysis released on Friday that the experimental psoriasis drug,...

» read full story

June 14th, 2008 - 09:06

FDA: J&J’s Psoriasis Drug Might Raise Cancer Risk

Johnson & Johnson’s experimental drug, ustekinumab appears to be effective in treating...

» read full story

June 16th, 2008 - 15:48